Will the new antipsychotics bring hope of reducing the risk of developing extrapyramidal syndromes and tardive dyskinesia?

International Clinical Psychopharmacology

Volumn 12, Issue SUPPL. 1, 1997, Pages

  Casey, Daniel E ^a,b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Extrapyramidal syndromes; Neuroleptics; Schizophrenia; Tardive dyskinesia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE;

CONFERENCE PAPER; EXTRAPYRAMIDAL SYNDROME; HUMAN; PRIORITY JOURNAL; TARDIVE DYSKINESIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DYSKINESIA, DRUG-INDUCED; HUMANS; RISK;

EID: 0030893254     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199705002-00005     Document Type: Conference Paper

References (61)

1. Arnt J, Hyttel J, Bach-Lauritsen T (1986) Further studies of the mechanism behind scopolamine-induced reversal of antistereotypic and cataleptogenic effects of neuroleptics in rats. Acta Pharmacol Toxicol 59:319-324.
2. Ayd FJ (1961) A survey of drug-induced extrapyramidal reactions. JAMA 175:1054-1060.
3. Baldessarini RJ, Cohen BM, Teicher MH (1988) Significance of neuroleptic dose and plasma level in pharmacological treatment of psychosis. Arch Gen Psychiatry 45:79-91.
4. Balsara JJ, Jadhav JH, Chandorkar AG (1979) Effect of drugs influencing the central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology 62:67-69.
5. Barnes TRE, Braude WM (1985) Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 42:874-878.
6. Beasley CM, Sanger W, Satterlee G, et al. (1996a) Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 124:159-167.
7. Beasley CM, Tollefson G, Tran P, et al. (1996b) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14:111-123.
8. Boyer WF, Bakalar NH, Lake CR (1989) Anticholinergic prophylaxis of acute haloperidol induced dystonic reactions. J Clin Psychopharmacol 7:164-166.
9. Bunney BS, Sesack SR, Silva N (1987) Midbrain dopaminergic systems: neurophysiology and electrophysiological pharmacology. In: Psychopharmacology: The Third Generation of Progress. Edited by Meltzer HY. New York: Raven Press; pp 113-126.
10. Casey DE (1989a) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99:S47-S53.
11. Casey DE (1989b) Serotonergic aspects of acute extrapyramidal syndromes in nonhuman primates. Psychopharmacol Bull 25: 457-459.
12. Casey DE (1991a) Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 4:109-120.
13. Casey DE (1991b) Extrapyramidal syndromes in nonhuman primates: typical and atypical neuroleptics. Psychopharmacol Bull 27:47-50.
14. Casey DE (1991c) Serotonin and dopamine relationships in nonhuman primate extrapyramidal syndromes. J Eur Coll Neuropsychopharmacol 3 (suppl 15):351-353.
15. Casey DE (1992a) Neuroleptic-induced acute dystonia. In: Drug-Induced Movement Disorders. Edited by Lang AE, Weiner WJ, Mount Kisko, New York: Futura; pp 21-40.
16. Casey DE (1992b) The rabbit syndrome. In: Disorders of Movement in Psychiatry and Neurology. Edited by Joseph AB, Young R. Cambridge: Blackwell; pp 139-142.
17. 2 (haloperidol) antagonists in drug-naive monkeys. Psychopharmacology 107: 18-22.
18. Casey DE (1994a) Motor and mental aspects of acute extrapyramidal syndromes. Acta Psychiatr Scand 89 (suppl 380): 14-20.
19. Casey DE (1994b) Schizophrenia: psychopharmacology. In: The Psychiatric Clinics of North America: Annual of Drug Therapy. Edited by Jefferson JW, Greist JH. Philadelphia: WB Saunders; pp 81-99.
20. Casey DE (1995a) Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. In: Schizophrenia. Edited by Hirsch S, Weinberger DR. Oxford: Blackwell; pp 546-565.
21. 2 and serotonin mechanisms. In: Schizophrenia: An Integrated View. Edited by Fog R, Gerlach J, Hemmingsen R. Copenhagen: Munksgaard Press; pp 287-297.
22. Casey DE (1995c) Tardive dyskinesia: pathophysiology. In: Psychopharmacology: The Fourth Generation of Progress. Edited by Bloom FE, Kupfer DJ. New York: Raven Press; pp 1497-1502.
23. Casey DE (1996) Behavioral effects of sertindole, risperidone, clozapine and haloperidol in cebus monkeys. Psychopharmacology 124:134-140.
24. Casey DE, Keepers GA (1988) Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. In: Psychopharmacology: Current Trends. Edited by Casey DE, Christensen AV. Berlin: Springer; pp 74-93.
25. Cohen BM, Keck PE, Satlin A, et al. (1991) Prevalence and severity of akathisia in patients on clozapine. Biol Psychiatry 29: 1215-1219.
26. Daniel D, Targum S, Zimbroff D, et al. (1995) Efficacy, safety and dose response of three doses of sertindole and three doses of haldol in schizophrenic patients [abstract 278]. In: American College of Neuropsychopharmacology 34th Annual Meeting. Nashville, Tennessee: American College of Neuropsychopharmacology.
27. Deniker P (1984) Introduction of neuroleptic chemotherapy into psychiatry. In: Discoveries in Biological Psychiatry. Edited by Ayd FJ, Blackwell B. Baltimore, Maryland: Ayd Medical Communications; pp 155-164.
28. 11C] raclopride. Psychopharmacology 107:23-29.
29. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544.
30. Ganzini L, Heintz R, Hoffman WF, et al. (1991) Acute extrapyramidal syndromes in neuroleptic-treated elders: a pilot study. J Geriatr Psychiatry Neurol 4:222-225.
31. Ganzini L, Casey DE, Hoffman WF, et al. (1992) Tardive dyskinesia and diabetes mellitus. Psychopharmacol Bull 28:281-286.
32. Gerlach J, Casey DE, Kistrup K, et al. (1988) Dopamine D-1 and D-2 receptor functions in acute extrapyramidal syndromes and tardive dyskinesia. In: Neurology and Neurobiology, vol 42C, Progress in Catecholamine Research. Part C: Clinical Aspects. Edited by Belmaker RH, Sandler M, Dahlstrom A. New York: Alan R Liss; pp 1-4.
33. Hansen LB, Larsen NE, Vestergard P (1981) Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects. Psychopharmacology 74:306-309.
34. Hirsch SR, Link CGG, Goldstein JM, et al. (1996) ICI 204,636: a new atypical antipsychotic drug. Br J Psychiatry 168:45-56.
35. 1 receptors (ex vivo radioreceptor binding studies). J Neural Transm 89:61-69.
36. Jeste DV, Potkin SG, Sinha S, et al. (1979) Tardive dyskinesia: reversible and irreversible. Arch Gen Psychiatry 36:585-590.
37. van Kammen DP, McEvoy JP, Targum S, et al. (1996) A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 124:168-175.
38. Kane JM, Jeste DV, Barnes TRE, et al. (1992) Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Association.
39. Keepers GA, Casey DE (1991) Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. Am J Psychiatry 148:85-89.
40. Keepers GA, Clappison VJ, Casey DE (1983) Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 40:1113-1117.
41. Keepers GA, Casey DE (1987) Prediction of neuroleptic-induced dystonia. J Clin Psychopharmacol 7:342-344.
42. Korsgaard S, Gerlach J, Christensson E (1985) Behavioral aspects of serotonin-dopamine interaction in the monkey. Eur J Pharmacol 118:245-252.
43. Kurz M, Hummer M, Oberbauer H, et al. (1995) Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology 118:52-56.
44. Levinson DF, Simpson GM, Singh H, et al. (1990) Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry 47:761-768.
45. Lewander T, Westerbergh S, Morrison D (1990) Clinical profile of remoxipride: a combined analysis of a comparative double-blind multicentre trial programme. Acta Psychiatr Scand 358: 92-98.
46. Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835.
47. Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin pKi values. J Pharmacol Exp Ther 251:238-246.
48. 2 dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology 106:433-438.
49. 2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment. Eur J Pharmacol 186:49-59.
50. Peacock L, Solgaard T, Lublin H, et al. (1996) Clozapine versus typical antipsychotics: a retro- and prospective study of EPS. Psychopharmacology 124:188-196.
51. Peuskens J (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166:712-726.
52. Povlsen UJ, Noring U, Laursen AL, et al. (1986) Effects of serotonergic and anticholinergic drugs in haloperidol-induced dystonia in cebus monkeys. Clin Neuropharmacol 9:84-90.
53. Saltz BL, Woerner M, Kane JM, et al. (1991) Prospective study of tardive dyskinesia incidence in the elderly. JAMA 266:2402-2406.
54. Sánchez C, Arnt J, Dragsted N, et al. (1991) Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 22:239-250.
55. Skarsfeldt T (1992) Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurons in rats: acute and repeated treatment. Synapse 10:25-33.
56. Snyder SH (1976) The dopamine hypothesis in schizophrenia: focus on the dopamine receptor. Am J Psychiatry 133:197-202.
57. Toenniessen LM, Casey DE, McFarland BH (1985) Tardive dyskinesia in the aged. Arch Gen Psychiatry 42:278-284.
58. Tune L, Coyle JT (1981) Acute extrapyramidal side effects: serum levels of neuroleptics. Psychopharmacology 75:9-15.
59. 4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610-614.
60. Villeneuve A (1972) The rabbit syndrome: a peculiar extrapyramidal reaction. Can Psychiatr Assoc J 17:69-72.
61. Waddington JL, O'Callaghan E, Larkin C, et al. (1993) Cognitive dysfunction in schizophrenia: organic vulnerability factor or state marker for tardive dyskinesia? Brain Cogn 23:56-70.